Compound Detail
CHEMBL3813873
PEXIDARTINIB 💊 Approved Drug
Enter ChEMBL ID:
Free Research Context
This compound will appear in recent viewed items on the research home for this browser.
Research home
View demo workspace
💊 Approved Drug
Basic Information
| ChEMBL ID | CHEMBL3813873 |
| Name | PEXIDARTINIB |
| Phase | Approved |
| Structure Type | MOL |
| InChI Key | JGWRKYUXBBNENE-UHFFFAOYSA-N |
| Therapeutic | ✓ Yes |
22
Targets
115
Activities
3
Assay Types
11
PK Parameters
20
Publications
4
Known Names
16
Indications
3
Mechanisms
Molecular Properties
417.8
MW (Da)
5.23
ALogP
4
HBA
2
HBD
66.5
PSA (Ų)
0.47
QED
1
Ro5 Violations
5
Rot. Bonds
Drug Information
| Molecule Type | Small molecule |
| First Approval | 2019 |
| Availability | Prescription |
| Chirality | Achiral |
Mechanism of Action
| Mechanism | Action Type | Target | Direct | Efficacy |
|---|---|---|---|---|
| Macrophage colony stimulating factor receptor inhibitor | INHIBITOR | Macrophage colony-stimulating factor 1 receptor | ✓ | ✓ |
| Tyrosine-protein kinase receptor FLT3 inhibitor | INHIBITOR | Receptor-type tyrosine-protein kinase FLT3 | ✓ | ✓ |
| Stem cell growth factor receptor inhibitor | INHIBITOR | Mast/stem cell growth factor receptor Kit | ✓ | ✓ |
Indications
Neoplasms Synovitis, Pigmented Villonodular Breast Neoplasms Breast Neoplasms Glioblastoma Hemangiosarcoma Hodgkin Disease Melanoma Melanoma Prostatic Neoplasms, Castration-Resistant Arthritis, Rheumatoid Gastrointestinal Stromal Tumors Leukemia, Myeloid, Acute Neurilemmoma Prostatic Neoplasms Liver Diseases
ATC Classification
L01EX15
pexidartinib
Level 1: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Level 2: ANTINEOPLASTIC AGENTS
Activity Summary
IC50 105 meas. best 9.96
Kd 8 meas. best 8.24
EC50 2 meas. best 6.7
Target Activity Profile
| Target | Type | Best pChEMBL | Mean pChEMBL | Best (nM) | # Data |
|---|---|---|---|---|---|
| BaF3 CHEMBL614524 | IC50 | 9.96 | 7.4217 | 0.1 | 12 |
| Unchecked CHEMBL612545 | IC50 | 8.8 | 7.71 | 1.6 | 4 |
| Macrophage colony-stimulating factor 1 receptor CHEMBL1844 | IC50 | 8.77 | 7.88 | 1.7 | 34 |
| Receptor-type tyrosine-protein kinase FLT3 CHEMBL1974 | IC50 | 8.3 | 7.6013 | 5.0 | 16 |
| Macrophage colony-stimulating factor 1 receptor CHEMBL1844 | Kd | 8.24 | 7.34 | 5.8 | 4 |
| Protein kinase C theta type CHEMBL3920 | Kd | 8.22 | 8.22 | 6.0 | 1 |
| Mast/stem cell growth factor receptor Kit CHEMBL1936 | IC50 | 8.16 | 7.6158 | 6.9 | 12 |
| Platelet-derived growth factor receptor alpha CHEMBL2007 | IC50 | 8.02 | 7.5 | 9.6 | 4 |
| Macrophage colony-stimulating factor 1 receptor CHEMBL5570 | IC50 | 7.85 | 7.425 | 14.0 | 2 |
| NT-3 growth factor receptor CHEMBL5608 | IC50 | 7.7 | 6.875 | 20.0 | 2 |
| NFS-60 CHEMBL614199 | IC50 | 7.48 | 7.48 | 33.0 | 2 |
| Platelet-derived growth factor receptor beta CHEMBL1913 | IC50 | 7.44 | 7.11 | 36.0 | 3 |
| Receptor-type tyrosine-protein kinase FLT3 CHEMBL1974 | Kd | 7.26 | 7.26 | 55.0 | 1 |
| BMDM CHEMBL4296525 | IC50 | 7.25 | 7.25 | 56.0 | 1 |
| MV4-11 CHEMBL613835 | IC50 | 6.7 | 6.7 | 200.0 | 1 |
| BaF3 CHEMBL614524 | EC50 | 6.7 | 6.7 | 200.0 | 1 |
| NFS-60 CHEMBL614199 | EC50 | 6.53 | 6.53 | 294.0 | 1 |
| MOLM-14 CHEMBL3706570 | IC50 | 6.46 | 6.2667 | 350.0 | 3 |
| Vascular endothelial growth factor receptor 2 CHEMBL279 | IC50 | 6.46 | 6.0333 | 350.0 | 3 |
| RAW264.7 CHEMBL612557 | IC50 | 6.4 | 6.385 | 400.0 | 2 |
| Aurora kinase B CHEMBL2185 | IC50 | 6.19 | 6.19 | 643.0 | 1 |
| Tyrosine-protein kinase Lck CHEMBL258 | IC50 | 6.07 | 6.07 | 860.0 | 1 |
| Vascular endothelial growth factor receptor 1 CHEMBL1868 | IC50 | 6.06 | 6.06 | 880.0 | 1 |
| Uncharacterized protein FLJ45252 CHEMBL4105933 | Kd | 5.84 | 5.84 | 1452.0 | 1 |
| SARS-CoV-2 CHEMBL4303835 | IC50 | 5.26 | 5.26 | 5430.0 | 1 |
| AP2-associated protein kinase 1 CHEMBL3830 | Kd | 4.86 | 4.86 | 13711.0 | 1 |
Pharmacokinetic Data
| Parameter | Value | Units | Species |
|---|---|---|---|
| AUC | 18891.0 | ng.hr.mL-1 | Mus musculus |
| CL | 0.8333 | mL.min-1.kg-1 | Mus musculus |
| CL | 11.8 | mL.min-1.g-1 | Homo sapiens |
| CL | 41.4 | mL.min-1.g-1 | Mus musculus |
| CL | 61.2 | mL.min-1.g-1 | Rattus norvegicus |
| CL | 0.8333 | mL.min-1.kg-1 | Mus musculus |
| CL | 41.0 | mL.min-1.g-1 | Mus musculus |
| CL | 12.0 | mL.min-1.g-1 | Homo sapiens |
| Fu | 0.99 | - | Mus musculus |
| T1/2 | 5.6 | hr | Mus musculus |
| T1/2 | 5.6 | hr | Mus musculus |
Activity Data Samples
Top measurements by pChEMBL value
Literature References
Data from ChEMBL 36 via Core Engine